ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.

ClinicalTrials.gov ID: NCT00611715

Public ClinicalTrials.gov record NCT00611715. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of Letrozole Plus OSI-774 (Tarceva) in Post-menopausal Women With ER and/or PR-Positive Metastatic Breast Cancer

Study identification

NCT ID
NCT00611715
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Enrollment
48 participants

Conditions and interventions

Conditions

Interventions

  • erlotinib hydrochloride Drug
  • fluorescence in situ hybridization Genetic
  • immunohistochemistry staining method Other
  • laboratory biomarker analysis Other
  • letrozole Drug

Drug · Genetic · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2003
Primary completion
Nov 30, 2008
Completion
Nov 30, 2008
Last update posted
Aug 8, 2012

2003 – 2008

United States locations

U.S. sites
9
U.S. states
3
U.S. cities
8
Facility City State ZIP Site status
Central Georgia Hematology/Oncology Associates, P.C. Macon Georgia 31201
Jennie Stuart Medical Center Hopkinsville Kentucky 42240
Purchase Cancer Group Paducah Kentucky 42002
Memorial Health Care System Chattanooga Tennessee 37404
The Jones Clinic - Germantown Germantown Tennessee 38138
Jackson-Madison County Hospital Jackson Tennessee 38301
Tennessee Cancer Specialists Knoxville Tennessee 37909
Vanderbilt-Ingram Cancer Center - Cool Springs Nashville Tennessee 37067
Vanderbilt-Ingram Cancer Center Nashville Tennessee 37232-6838

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00611715, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 8, 2012 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00611715 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →